NCT00151996View on ClinicalTrials.gov

Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

August 16, 2004

Primary Completion Date

December 27, 2004

Study Completion Date

December 27, 2004

Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
DRUG

Methylphenidate + SPD503 (Guanfacine hydrochloride)

DRUG

Amphetamine + SPD503

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY

NCT00151996 - Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD) | Biotech Hunter | Biotech Hunter